Curr Opin Nephrol Hypertens. 2005;14(6):543–9.PubMedCrossRef 5. Wabel P, et al. Importance of whole-body bioimpedance spectroscopy for the management of fluid I BET 762 balance. Blood Purif.

2009;27(1):75–80.PubMedCrossRef 6. Koziolek MJ, et al. Bioimpedance analysis and intradialytic hypotension in intermittent hemodialysis. Clin Nephrol. 2006;66(1):39–50.PubMed 7. Chertow GM, et al. Vintage, nutritional status, and survival in hemodialysis patients. Kidney Int. 2000;57(3):1176–81.PubMedCrossRef 8. Chazot C, Wabel P, Chamney P, Moissl U, Wieskotten S, Wizemann V. Importance of normohydration for the long-term survival of haemodialysis patients. Nephrol Dial Transplant. 2012; 27:2404–10. 9. Katzarski KS, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant. 1999;14(2):369–75.PubMedCrossRef 10. Cheigh JS, et al. Hypertension OSI-027 is not adequately controlled in hemodialysis patients. Am J Kidney Dis. 1992;19(5):453–9.PubMed 11. Zhu F, et al. Estimation of normal hydration in dialysis patients using

whole body and calf bioimpedance analysis. Physiol Meas. 2011;32(7):887–902.PubMedCrossRef 12. Cheriex EC, et al. Echography of the inferior vena cava is a simple and reliable tool for estimation of ‘dry weight’ in haemodialysis patients. Nephrol Dial Transplant. 1989;4(6):563–8.PubMed”
“Introduction IgA nephropathy (IgAN), a major component of chronic glomerulonephritis, causes end-stage renal disease in up to 50 % of affected patients [1]. Although proteinuria Anlotinib ic50 has been considered one of the most important predictors of renal outcome [2–6], few studies have clarified what degree of proteinuria at an early phase after initial treatment predicts renal survival. Donadio et al. [7] showed a lower amount of proteinuria at 1 year after the introduction of treatment to be associated with a better renal survival. However, they did not define the proteinuria level predicting a favorable renal outcome. Among the many clinical trials demonstrating the efficacy of steroid therapy

for IgAN [8–10], a randomized controlled trial by Pozzi NADPH-cytochrome-c2 reductase et al. [11, 12] clearly demonstrated that 6 months of steroid therapy significantly reduced the risk of a 100 % increase in serum creatinine from the baseline compared to conventional therapy during a 5- or 10-year follow-up. They demonstrated that the steroid therapy induced the lowest level of proteinuria at 1 year of follow-up. We herein aimed to define the target level of proteinuria at 1 year after initiating steroid therapy to establish a prognostic threshold for a favorable renal survival of IgAN patients. Subjects and methods Patients and study design We collected the medical records from 169 patients with IgAN who received 6 months of steroid therapy between 2004 and 2010 in four affiliated hospitals of Jikei University School of Medicine, employing a historical cohort design.